Mac Lochlainn, Dylan J <br/><br/>
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.  [electronic resource] 

 -  Molecular genetics and metabolism  02 2018 
 - 154-158 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1096-7206 
<br/><br/><label>Standard No.: </label>10.1016/j.ymgme.2017.10.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Double-Blind Method<br/>Enzyme Replacement Therapy<br/>Fabry Disease--enzymology<br/>Humans<br/>Isoenzymes--administration & dosage<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Recombinant Proteins--administration & dosage<br/>Retrospective Studies<br/>Severity of Illness Index<br/>alpha-Galactosidase--administration & dosage